Recro Pharma

The FDA Turns Recro Pharma (REPH) Away, But This Analyst Remains Bullish

Recro Pharma (NASDAQ:REPH) received devastating news on Thursday. The U.

Recro Pharma (REPH) Stock’s Crashing; Here’s What Investors Need to Know

Recro Pharma (NASDAQ:REPH) announced today thatĀ its lead compound, IV Meloxicam, received a CRL from the FDA, which is a nice way of saying …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts